Supernus Pharmaceuticals Inc. said its board approved updated executive compensation following an annual review, effective Jan. 1, 2026. CEO Jack A. Khattar’s base salary rose to $1,067,100 from $1,036,000, with a 2025 bonus of $846,930 and equity awards of options for 341,610 shares plus 204,966 performance share units; his 2026 bonus target remains 75% of base salary. CFO Timothy C. Dec’s base salary increased to $525,100 from $504,900, with a 2025 bonus of $233,894 and equity awards including options for 17,500 shares, 3,000 restricted stock units and 3,500 PSUs; his 2026 bonus target remains 45% of base salary. The company also raised base salaries and granted 2025 bonuses and equity awards to other senior executives, with stock options priced at $50.20 per share and time-based options and RSUs vesting in equal annual installments over four years, while PSUs vest based on performance goal achievement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001356576-26-000007), on February 24, 2026, and is solely responsible for the information contained therein.
Comments